Condreay LD, et al. - Using data from two clinical studies (n = 610 subjects) ie, METREX (NCT02105948) and METREO (NCT02105961), researchers performed genome-wide association analyses to investigate genetic variants related to the effectiveness of mepolizumab (a humanized monoclonal antibody to IL-5) in COPD. Participants had elevated eosinophil levels (≥150 cells/μL at screening or ≥300 cell/μL in the 12 months before the study) and had received mepolizumab. According to the findings of this exploratory study in COPD patients with peripheral blood eosinophilia, no genetic influences on mepolizumab-treatment response were found.